Biophytis SA

07/18/2025 | Press release | Distributed by Public on 07/18/2025 10:28

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia (Form 6-K)

Biophytis Partners in AI with Lynx Analytics

to Accelerate Drug Discovery for Sarcopenia

Paris (France) and Cambridge (Massachusetts, États-Unis), July 15, 2025 - 07:00am - Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to accelerate the discovery and development of novel small molecule drugs for the treatment of sarcopenia, a debilitating condition characterized by progressive loss of muscle mass and strength in old adults.

Sarcopenia represents a significant and growing unmet medical need, with no FDA-approved therapies currently available. By leveraging Lynx's advanced AI expertise, Biophytis will be able to rapidly identify and optimize small molecules that can be efficient in muscle preservation and regeneration. This partnership will unite Biophytis' expertise in age-related disease biology with Lynx's cutting-edge computational technologies, enabling a more efficient and targeted approach to drug development.

The partnership will focus on:

· Utilizing AI algorithms to mine biomedical data.
· Accelerating preclinical validation and candidate selection through in silico modeling and advanced analytics.
· Building a robust pipeline of drug candidates with the potential to restore muscle function and improve quality of life for individuals affected by sarcopenia.

"Our collaboration with Lynx Analytics marks a transformative step in our mission to address sarcopenia at its root cause," said Stanislas Veillet, CEO of Biophytis. "By integrating artificial intelligence into our drug discovery process, we aim to significantly reduce the time and cost required to bring effective therapies to patients in need."

"Our AI platforms combine scaffold hopping tools, Biological Language Models, and Accelerated Compute for biology to streamline the discovery process," adds Gyorgy Lajtai, CEO of Lynx Analytics. "We're proud to support Biophytis in reducing the time and cost needed to bring effective therapies to patients »

This partnership underscores the growing importance of interdisciplinary collaboration in tackling age-related diseases and highlights the potential of AI to transform the drug discovery landscape.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

About Lynx Analytics

Lynx Analytics is a trusted AI partner to the life sciences industry, helping pharma and biotech companies accelerate drug discovery, improve clinical development, and boost commercial outcomes. Central to this is LynxKite 2000:MM-an AI-driven workflow builder designed for pharmaceutical R&D. It allows scientists-including Lynx Analytics' own computational biology experts-to rapidly integrate biomedical data, biology-focused foundation models, and cloud-scale computing, either visually or through code, making it an essential tool for preclinical research. For more information, visit https://www.lynxanalytics.com

Biophytis SA published this content on July 18, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on July 18, 2025 at 16:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io